He is now the chief scientist of Beijing Zhaoyan New Drug Research Center Co., Ltd. He once served as a regulatory pathologist certified and authorized by FDA's scientific investigation office. He has the qualification and power to review and evaluate the pathological data submitted by preclinical research institutions. He is a well-known expert in pharmacology, toxicology and pathology of FDA in the United States and an internationally well-known GLP regulatory expert.

He is a neuropharmacologist, specializing in ophthalmic pharmacology for nearly 30 years. After receiving his doctorate from Stanford University, he completed his postdoctoral research at Yale University and Rockefeller University. He has taught in the Department of Neurobiology at Washington University in St. Louis for 14 years, focusing on the study of the structure, function and pathological mechanism of neurotransmitters, growth factors and their receptors, and has published many related papers.

More than 20 years of experience in ophthalmic research and development. Although his main research area is glaucoma, he has made significant contributions to the drug development of wet AMD, dry eye and hereditary retinal diseases. Dr. Mallick previously served as vice president of clinical research / glaucoma at Aerie pharmaceuticals.

Dr. Nakamura has many years of working experience in pharmaceutical companies in Japan. He received a master's degree in pharmacy from Osaka University and a doctor's degree from the medical school of Yamaguchi University. His focus is on the physiology and pharmacology of the eye, especially the ocular surface. He participated in the research and development of Shentian pharmaceutical's dry eye products such as hyaluronic acid and diquaforsol tetrasodium, and led the establishment of the dry eye drug market in Japan.

Currently, he is the co-founder and vice president of jenivision company in the United States. He has successively worked in Smith Kline, Allergan and other pharmaceutical companies, and has many year

He once served as the senior vice president and chief scientist (CSO) of Swiss Alcon company, responsible for all key scientific research work in the fields of drugs, surgical instruments (intraocular